Loading...
•
Sep 30, 2023
Aytu BioScience Q1 2024 Earnings Report
Aytu BioPharma reported results for the first quarter of fiscal 2024, featuring a net revenue of $22.1 million and adjusted EBITDA of $2.2 million.
Key Takeaways
Aytu BioPharma reported a decrease in total net revenue to $22.1 million compared to $27.7 million in the previous year, primarily due to the wind down of the Consumer Health segment. The Rx segment's net revenue was $17.8 million, with ADHD product revenue increasing by 31%. The company reported a net loss of $8.1 million, impacted by a $5.9 million loss on derivative warrant liabilities.
Total net revenue was $22.1 million, a decrease from $27.7 million year-over-year, mainly due to the planned wind down of the Consumer Health segment.
ADHD product net revenue increased by 31% to $15.1 million compared to $11.6 million in the prior year.
The Company’s Rx segment net revenue was $17.8 million compared to $18.7 million in the year-ago quarter.
Cash and cash equivalents totaled $20.0 million as of September 30, 2023.
Forward Guidance
Aytu BioPharma is focusing on its Rx segment and winding down its Consumer Health segment to drive long-term shareholder value. The company expects to sell through the remaining Consumer Health inventory, resulting in approximately neutral Adjusted EBITDA for the segment in fiscal 2024.
Positive Outlook
- Ramping up manufacturing at contract manufacturer.
- Focusing on growth and profitability in Rx segment.
- Expecting normalization of unit shipments in Pediatrics.
- Implementing strategies to deepen Pediatrics prescriptions.
- Exploring possible monetization opportunities for consumer health brands.
Challenges Ahead
- Winding down Consumer Health segment.
- Impacted by payor changes in Pediatrics.
- Impacted by timing of customer ordering in Pediatrics.
- Suspension of pipeline clinical development programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...